Literature DB >> 15047131

Insulin-like growth factor-I/insulin-like growth factor binding protein-3 alters lymphocyte responsiveness following severe burn.

Steven E Wolf1, Kenneth J Woodside, Roque J Ramirez, Makiko Kobayashi, Fujio Suzuki, David N Herndon.   

Abstract

PURPOSE: Following severe burn, patients are immunocompromised, making them at increased risk for infection. Exogenous growth hormone has been shown to partially restore immune function. Herein, we investigated Th1/Th2 cytokine profiles and cellular proliferation in isolated mononuclear cells after treatment with exogenous insulin-like growth factor-I (IGF-I), the indirect mediator of many growth hormone effects, in severely burned patients.
METHODS: Eight children and 2 adults with >20% total body surface area burns were prospectively randomized to receive either placebo or 4 mg/kg rhIGF-I/IGFBP-3 for one-week intervals (2 groups), with another group receiving placebo for both cycles. Normal children were examined for comparison. Isolated whole blood lymphocyte production of Th1 (IL-2, IFN-gamma) and Th2 (IL-4, IL-10) cytokines, and proliferative responses to specific T-cell mitogens were measured.
RESULTS: Depressed Th1 and exaggerated Th2 cytokine responses were seen in all burned subjects compared to non-burned controls (P < 0.05). IL-2 and IFN-gamma production increased in patients treated with IGF-I/IGFBP-3 (P < 0.05). IL-4 production significantly decreased, while IL-10 levels did not change. Cytokine production did not change in those receiving two courses of placebo. Proliferative responses of isolated mononuclear cells to IL-2 as a Th1 specific mitogen increased with IGF-I/IGFBP-3 treatment (P < 0.05).
CONCLUSIONS: Following severe burn, a shift occurs toward a predominant Th2 phenotype. Exogenous IGF-I/IGFBP-3 treatment partially reverses this response.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15047131     DOI: 10.1016/S0022-4804(03)00305-6

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  7 in total

1.  Aging and the pathogenic response to burn.

Authors:  Meenakshi Rani; Martin G Schwacha
Journal:  Aging Dis       Date:  2011-07-04       Impact factor: 6.745

2.  Microfluidics for T- lymphocyte cell separation and inflammation monitoring in burn patients.

Authors:  Alan E Rosenbach; Piyush Koria; Jeremy Goverman; Kenneth T Kotz; Amit Gupta; Ming Yu; Shawn P Fagan; Daniel Irimia; Ronald G Tompkins
Journal:  Clin Transl Sci       Date:  2011-02       Impact factor: 4.689

Review 3.  Anabolic and anticatabolic agents used in burn care: What is known and what is yet to be learned.

Authors:  Eduardo I Gus; Shahriar Shahrokhi; Marc G Jeschke
Journal:  Burns       Date:  2019-12-15       Impact factor: 2.744

Review 4.  Cardiovascular Dysfunction Following Burn Injury: What We Have Learned from Rat and Mouse Models.

Authors:  Ashley N Guillory; Robert P Clayton; David N Herndon; Celeste C Finnerty
Journal:  Int J Mol Sci       Date:  2016-01-02       Impact factor: 5.923

Review 5.  Acromegaly, inflammation and cardiovascular disease: a review.

Authors:  Thalijn L C Wolters; Mihai G Netea; Niels P Riksen; Adrianus R M M Hermus; Romana T Netea-Maier
Journal:  Rev Endocr Metab Disord       Date:  2020-12       Impact factor: 6.514

6.  Insulin-like growth factor-1 induces regulatory T cell-mediated suppression of allergic contact dermatitis in mice.

Authors:  Bjarki Johannesson; Susanne Sattler; Ekaterina Semenova; Saveria Pastore; Teresa M Kennedy-Lydon; Robert D Sampson; Michael D Schneider; Nadia Rosenthal; Daniel Bilbao
Journal:  Dis Model Mech       Date:  2014-08       Impact factor: 5.758

Review 7.  Innate Immune System Response to Burn Damage-Focus on Cytokine Alteration.

Authors:  Olga Sierawska; Paulina Małkowska; Cansel Taskin; Rafał Hrynkiewicz; Paulina Mertowska; Ewelina Grywalska; Tomasz Korzeniowski; Kamil Torres; Agnieszka Surowiecka; Paulina Niedźwiedzka-Rystwej; Jerzy Strużyna
Journal:  Int J Mol Sci       Date:  2022-01-10       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.